Incyte (INCY) Capital Expenditures (2010 - 2026)
Incyte (INCY) reported Capital Expenditures of $10.2 million for Q1 2026, up 221.87% on a YoY basis from $3.2 million in Q1 2025, and down 81.36% quarter-over-quarter from $54.7 million in Q4 2025.
Incyte (INCY) Capital Expenditures (2010 - 2026) Analysis & Trends
Incyte has reported Capital Expenditures for 17 years, with the latest figure at $10.2 million in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 221.87% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $65.9 million (up 1124.19% YoY), and the FY2025 full-year result was $58.9 million, up 2166.73% from the prior year.
- Capital Expenditures for Q1 2026 stood at $10.2 million, down from $54.7 million in the prior quarter.
- The five-year high for Capital Expenditures was $54.7 million in Q4 2025, with the low at -$53.1 million in Q4 2022.
- Historically, Capital Expenditures has averaged $6.3 million across 5 years, with a median of $3.2 million in 2025.
- Annual changes were most pronounced in 2023 — Capital Expenditures slumped 169.15% — and 2025, when it surged 5913.92%.
- Incyte's Capital Expenditures stood at -$53.1 million in 2022, then surged by 161.2% to $32.5 million in 2023, then tumbled by 102.9% to -$941000.0 in 2024, then surged by 5913.92% to $54.7 million in 2025, then tumbled by 81.36% to $10.2 million in 2026.
- The last three Capital Expenditures figures came in at $10.2 million (Q1 2026), $54.7 million (Q4 2025), and $112000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 10.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.20 Mn |
| Mar 31, 2026 | 10.20 Mn |
| Dec 31, 2025 | 54.71 Mn |
| Dec 31, 2025 | 54.71 Mn |
| Sep 30, 2025 | 112,000.00 |
| Sep 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 877,000.00 |
| Jun 30, 2025 | 877,000.00 |
| Mar 31, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | -941,000.00 |
| Dec 31, 2024 | -941,000.00 |
| Sep 30, 2024 | 2.74 Mn |
| Sep 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | 417,000.00 |
| Jun 30, 2024 | 417,000.00 |
| Mar 31, 2024 | 383,000.00 |
| Mar 31, 2024 | 383,000.00 |
| Dec 31, 2023 | 32.48 Mn |
| Dec 31, 2023 | 32.48 Mn |